Variances in the mRNA expression profile of TGF-β1-3 isoforms and its TGF-βRI-III receptors during cyclosporin a treatment of psoriatic patients.

INTRODUCTION

Psoriasis is a chronic, immunologic, multi-factor inflammatory skin disease, strongly associated with a higher level of a number of cytokines, such as isoforms of transforming growth factor β (TGF-β1-3) and its receptors (TGF-βRI-III). One of the most popular and important drugs used to treat this disease is cyclosporin A (CsA).

AIM

The aim of this study was to investigate the expression of genes encoding the transforming growth factor (TGF)-β isoforms and receptors of the cytokine TGF-βRs in psoriatic patients during an 84-day long observation of the effects of cyclosporin A therapy. It made an attempt to determine the usefulness of testing mRNA expression of β- and its receptors β as the supplementary molecular markers of lost sensitivity to the medicine.

MATERIAL AND METHODS

The study group consisted of 32 patients with psoriasis (20 men and 12 women) treated with cyclosporin A. The changes in expression patterns of β and β were performed by real-time quantitative reverse transcription PCR (RTqPCR).

RESULTS

The expression of β and β were detected in the whole period of therapy with CsA. Changes in transcriptional activities of β and β during pharmacotherapy were observed. Differences in the expression of these genes were found before and after 42 and 84 days of using CsA.

CONCLUSIONS

The changes in expression profiles of β and β during CsA therapy can be a useful molecular marker of lost sensitivity to the medicine.